This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mueller, T. Articles by Haidinger, D. Search for Related Content PubMed PubMed Citation Articles by Mueller, T. Articles by Haidinger, D. Social Bookmarking                         What's this?

Monitoring Aspirin 1 00 mg and Clopidogrel 75 mg Therapy with the PFA-1 00 Device in Patients with Peripheral Arterial Disease

Meinhard Haltmayer, MD

Department of Laboratory Medicine, University of Linz, Austria

Werner Poelz, PhD

Department of Applied System Sciences and Statistics, University of Linz, Austria

Dieter Haidinger, MD

Department of Surgery (Division of Vascular Surgery), Konventhospital Barmherzige Brueder Linz, University of Linz, Austria

A tool to identify vascular patients who receive antiplatelet therapy and to distinguish between responders and non-responders to antiplatelet therapy could be of clinical importance. The present observational study was designed to investigate whether the PFA-1 00± device (Dade Behring) is suitable to detect long-term therapy of aspirin (100 mg/d) and/or clopidogrel (75 mg/d) in a cohort of patients with peripheral arterial disease (PAD). A total of 150 consecutive patients with PAD were studied; 34 patients were excluded from the study due to irregular intake of antiplatelet therapy or due to method limitations. Of the remaining 1 16 patients, 42 had no antiplatelet therapy, 47 had daily aspirin (100 mg) intake, 19 were administered clopidogrel 75 mg daily, and 10 received a medication with 100 mg aspirin plus clopidogrel 75 mg daily, all for at least 10 days. Nonparametric Kruskal-Wallis test with post hoc comparisons showed that collagen plus epinephrine (CEPI) closure times of the patient group receiving aspirin and the group receiving aspirin plus clopidogrel were similar (p > 0.05). In contrast, both patient groups exhibited prolonged CEPI values compared to patients without antiplatelet therapy and patients taking clopidogrel (p <0.001). Finally, both patients without antiplatelet therapy and patients with clopidogrel did not show marked differences with respect to their CEPI values (p>0.05). However, Kruskal-Wallis test results revealed that collagen plus adenosine-5'-diphosphate closure times were not significantly different in all four patient groups (p=0.257). In conclusion, the PFA-100' device may be a suitable tool for monitoring aspirin 100 mg therapy, but it is not appropriate for the detection of clopidogrel administration in its current setup. Although it appears plausible that patients with PAD could benefit from monitoring platelet inhibition, clear evidence for this concept is still lacking.

Vascular and Endovascular Surgery, Vol. 37, No. 2, 117-123 (2003)
DOI: 10.1177/153857440303700206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Mueller, B. Dieplinger, W. Poelz, and M. Haltmayer Utility of the PFA-100 Instrument and the Novel Multiplate Analyzer for the Assessment of Aspirin and Clopidogrel Effects on Platelet Function in Patients With Cardiovascular Disease Clinical and Applied Thrombosis/Hemostasis, December 1, 2009; 15(6): 652 - 659. [Abstract] [PDF]

				C. Velik-Salchner, S. Maier, P. Innerhofer, W. Streif, A. Klingler, C. Kolbitsch, and D. Fries Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study Anesth. Analg., December 1, 2008; 107(6): 1798 - 1806. [Abstract] [Full Text] [PDF]